Loading…
Monte Rosa Therapeutics, Inc. is projected to rise to $35.08 by 2027, a +55% move from its current price of $22.68. GLUE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $22.02 | $22.69 | $23.37 | +0.02% |
| Aug 2 | $21.75 | $22.69 | $23.67 | +0.05% |
| Aug 3 | $21.55 | $22.70 | $23.90 | +0.07% |
| Aug 4 | $21.39 | $22.70 | $24.10 | +0.10% |
| Aug 5 | $21.24 | $22.71 | $24.27 | +0.12% |
| Aug 6 | $21.11 | $22.71 | $24.44 | +0.14% |
| Aug 7 | $20.99 | $22.72 | $24.59 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $20.99 | $22.72 | $24.59 | +0.17% |
| Week 2 | $20.35 | $22.76 | $25.44 | +0.33% |
| Week 3 | $19.88 | $22.79 | $26.14 | +0.50% |
| Week 4 | $19.49 | $22.83 | $26.74 | +0.67% |
| Week 5 | $19.17 | $22.87 | $27.29 | +0.83% |
| Week 6 | $18.88 | $22.91 | $27.80 | +1.00% |
| Week 7 | $18.62 | $22.95 | $28.28 | +1.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company that develops novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Its orally bioavailable molecular glue degraders (MGDs) include MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. It also develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Its pipeline spans immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases.
It also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has strategic collaborations and licensing agreements with Roche Ltd. and Novartis.
The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Monte Rosa Therapeutics, Inc. (GLUE) is a healthcare company currently trading at $22.04 per share, with a market capitalization of $1.86B and a rank of 2023.
The price outlook shows a path of growth over the multi-year horizon, with the 2026 forecasted average price at $22.04 and a progression higher in subsequent years. By 2030 the average is projected at $54.06, rising further to $231.29 by 2040 and to $473.85 by 2050. These figures come with corresponding increases in forecasted upside, culminating in substantial long-term upside in the later years.
The forecast series also implies meaningful upside potential in later years, with notable ROIs including 55.5 for 2027, 85.6 for 2028, 117.5 for 2029, 145.3 for 2030, 189.1 for 2031, 231.4 for 2032, 316.5 for 2033, 443.8 for 2034, 475.3 for 2035, 949.4 for 2040, and 2049.9 for 2050.
A major floor 35.1% below — a decisive break under it would weaken the trend.
The nearest floor, 19.3% below — buyers have tended to step in here.
The nearest ceiling, 8.3% above — a clean break opens room to run.
A major ceiling 23.9% above — clearing it would confirm fresh momentum.
Key GLUE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GLUE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $22.32 | Buy | $22.43 | Buy |
| MA 10 | $23.01 | Sell | $22.71 | Sell |
| MA 20 | $23.28 | Sell | $22.64 | Buy |
| MA 50 | $20.80 | Buy | $21.43 | Buy |
| MA 100 | $19.33 | Buy | $20.01 | Buy |
| MA 200 | $18.13 | Buy | $17.49 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.93 | Neutral |
| Stoch RSI (14) | 37.26 | Neutral |
| CCI (20) | -59.52 | Neutral |
| Williams %R (14) | -62.67 | Info |
| MACD (12,26,9) | -0.34 | Sell |
| ROC (12) | -3.32 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 37.33 | Neutral |
| TRIX (15) | 0.51 | Buy |
| Awesome (5,34) | 0.27 | Buy |
| Ultimate (7,14,28) | 43.28 | Neutral |
| Momentum (10) | -0.48 | Sell |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 21.74 | Buy |
| ADX (14) | 17.53 | Neutral |
| ATR (14) | 0.63 | Info |
The 30-day technical picture is bullish. RSI14 is 50 and the moving averages show a constructive short-term trend, with SMA50 at $20.57 and SMA200 at $17.93. Near-term support is at $17.76 and resistance at $24.56.
The 30-day range runs from a low of $18.09 to a high of $26.86, indicating a relatively wide swing within a bullish context. Annualized volatility is 60%, underscoring notable near-term variability within the trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.40 | $22.68 | $32.77 | 0% | Neutral | |
| $27.73 | $35.08 | $47.05 | +55% | Bullish | |
| $32.19 | $42.00 | $58.67 | +85% | Bullish | |
| $36.73 | $49.17 | $70.88 | +117% | Bullish | |
| $40.33 | $55.25 | $81.76 | +144% | Bullish | |
| $46.82 | $65.48 | $99.16 | +189% | Bullish | |
| $52.70 | $75.14 | $116.14 | +231% | Bullish | |
| $64.75 | $94.03 | $148.05 | +315% | Bullish | |
| $83.22 | $122.96 | $196.93 | +442% | Bullish | |
| $86.61 | $130.11 | $211.69 | +474% | Bullish | |
| $146.67 | $237.64 | $412.98 | +948% | Bullish | |
| $263.05 | $486.21 | $929.59 | +20.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $14.40 | $22.68 | $26.48 | +0.00% |
| August 2026 | $19.44 | $22.86 | $27.54 | +0.80% |
| September 2026 | $19.53 | $23.18 | $28.33 | +1.38% |
| October 2026 | $20.68 | $24.72 | $30.57 | +6.65% |
| November 2026 | $21.50 | $25.86 | $32.28 | +4.64% |
| December 2026 | $21.53 | $26.04 | $32.77 | +0.67% |
Click any year to see its month-by-month GLUE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GLUE could reach as high as $32.77, with a base case around $22.68 and support toward $14.40 — roughly 0% from $22.68. Price action looks broadly range-bound.
Expect GLUE to range from $27.73 to $47.05 through 2027. The $35.08 average target implies a +55% move from current prices. That is up +55% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The GLUE price prediction for 2028 points to an average of $42.00 (low $32.19, high $58.67) — a potential gain of +85% on today's $22.68. Momentum favours further upside here.
In 2029, GLUE is projected to trade between $36.73 and $70.88, averaging $49.17 — a potential gain of +117% from today's $22.68. That is up +17% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Monte Rosa Therapeutics, Inc.'s 2030 outlook centres on $55.25, within a $40.33 to $81.76 range. That is up +12% on the projected 2029 average. That marks a +144% change versus current levels. Momentum favours further upside here.
By 2031, GLUE could reach as high as $99.16, with a base case around $65.48 and support toward $46.82 — roughly +189% from $22.68. Buyers look set to stay in control over this stretch.
Expect GLUE to range from $52.70 to $116.14 through 2032. The $75.14 average target implies a +231% move from current prices. That is up +15% on the projected 2031 average. Momentum favours further upside here.
The GLUE price prediction for 2033 points to an average of $94.03 (low $64.75, high $148.05) — a potential gain of +315% on today's $22.68. Buyers look set to stay in control over this stretch.
In 2034, GLUE is projected to trade between $83.22 and $196.93, averaging $122.96 — a potential gain of +442% from today's $22.68. That is up +31% on the projected 2033 average. Momentum favours further upside here.
Monte Rosa Therapeutics, Inc.'s 2035 outlook centres on $130.11, within a $86.61 to $211.69 range. That is up +6% on the projected 2034 average. That marks a +474% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, GLUE could reach as high as $412.98, with a base case around $237.64 and support toward $146.67 — roughly +948% from $22.68. Momentum favours further upside here.
Expect GLUE to range from $263.05 to $929.59 through 2050. The $486.21 average target implies a +20.4x move from current prices. That is up +105% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GLUE today (≈ 44.091711 GLUE) could be worth
$21,437.68
+$20,437.68 (+2044%) by 2050 · US Dollar
Based on the average projected GLUE price of $486.21 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GLUEwould be worth at today's price.
$1,000 invested in GLUE on Jul 30, 2025 (≈ 179.211472 GLUE) would be worth
$4,064.52
+$3,064.52 (+306.5%) today · 4.06× · US Dollar
Based on a GLUE entry price of $5.58 vs. today's $22.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $23.03 | $984.8 | -1.5% |
| 1 month ago | $24.2 | $937.19 | -6.3% |
| 3 months ago | $18.8 | $1,206.38 | +20.6% |
| 6 months ago | $20.52 | $1,105.26 | +10.5% |
| 1 year ago | $5.58 | $4,064.52 | +306.5% |
| All time (5.0y) ago | $25.67 | $883.52 | -11.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GLUE forecast.
Our base-case forecast reaches $45.00 around 2029.
Implied market cap at $45.00: $3.8B
The multi-year forecast portrays a bullish trajectory across the long horizon, with the average price rising from $34.27 in 2027 to $40.91 in 2028, $47.93 in 2029 and $54.06 in 2030. By 2031 the avg is $63.71 and by 2032 it is $73.03, continuing to $91.79 in 2033 and $119.86 in 2034, then $126.79 in 2035. The longer-term path accelerates, with 2040 avg $231.29 and 2050 avg $473.85, reflecting a deepening bullish outlook.
Corresponding ROIs rise meaningfully over time, from 55.5 in 2027 to 145.3 in 2030, 189.1 in 2031, 231.4 in 2032, 316.5 in 2033, 443.8 in 2034, 475.3 in 2035, 949.4 in 2040, and 2049.9 in 2050. These figures illustrate substantial long-run upside but remain estimates, not guarantees, and actual results will depend on development progress, clinical outcomes, and broader market conditions.
Tap a question to reveal the answer.
2030 avg $54.06; min $39.42; max $80.09; ROI 145.3; sentiment BULLISH.
Forecasts show a trajectory of rising averages from 2027 onward (2027 avg $34.27; 2028 $40.91; 2029 $47.93; 2030 $54.06) with increasing ROIs (55.5% in 2027 to 145.3% in 2030, and higher thereafter) and a bullish long-term sentiment.
Yes. The 2033 avg is $91.79 and the 2034 avg is $119.86, with the 2034 max $192.22, indicating potential to cross $100 around 2034.
Current price is $22.04 and market cap is $1.86B.
The 30-day range is $18.09 to $26.86; RSI14 is 50; SMA50 is $20.57; SMA200 is $17.93; support is $17.76 and resistance is $24.56; annualized volatility is 60%.
Monte Rosa Therapeutics, Inc. Community Discussion
0Share your Monte Rosa Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.